These findings highlight KIFC1 as a potential biomarker to predict disease aggressiveness KIFC1 may also serve as a cancer-selective therapeutic target for high-grade serous ovarian adenocarcinoma patients. This evidence concerns the gene KIFC1 and ovarian serous adenocarcinoma.